74 studies found for:    Empagliflozin
Show Display Options
Rank Status Study
1 Completed
Has Results
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Empagliflozin medium placebo;   Drug: Empagliflozin low placebo;   Drug: Empagliflozin high placebo;   Drug: Empagliflozin medium;   Drug: Empagliflozin low;   Drug: Empagliflozin high
2 Completed
Has Results
Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food
Condition: Healthy
Interventions: Drug: BI 10773/linagliptin;   Drug: BI 10773/linagliptin SID;   Drug: BI 10773/linagliptin FDC
3 Completed Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
Conditions: Diabetes Mellitus, Type 2;   Hyperglycemia
Interventions: Drug: Metformin 500 mg bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin low dose qd;   Drug: Empagliflozin high dose qd;   Drug: Empagliflozin low dose bid;   Drug: Empagliflozin high dose bid
4 Active, not recruiting Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects
Condition: Healthy
Interventions: Drug: metformin;   Drug: empagliflozin/metformin;   Drug: empagliflozin
5 Completed Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female
Condition: Healthy
Interventions: Drug: metformin;   Drug: empagliflozin/metformin;   Drug: empagliflozin
6 Completed
Has Results
Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers
Condition: Healthy
Interventions: Drug: BI 10773 25 mg;   Drug: Warfarin 25 mg;   Drug: Warfarin
7 Completed A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: empagliflozin (low dose qd);   Drug: Empagliflozin (high dose qd);   Drug: empagliflozin (high dose bid);   Drug: empagliflozin (low dose bid)
8 Completed Bioavailability of Empagliflozin/Metformin Fixed Dose Combination(FDC) in Healthy Chinese Volunteers
Condition: Healthy
Interventions: Drug: 5 mg empagliflozin/850 mg metformin FDC;   Drug: 12.5 mg empagliflozin;   Drug: 850 mg metformin;   Drug: 5 mg empagliflozin;   Drug: 12.5 mg empagliflozin/850 mg metformin FDC;   Drug: 12.5 mg empagliflozin/500 mg metformin FDC;   Drug: 5 mg empagliflozin/500 mg metformin FDC;   Drug: 500 mg metformin
9 Not yet recruiting Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Linagliptin;   Other: Placebo;   Drug: Empagliflozin
10 Completed Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets
Condition: Healthy
Interventions: Drug: Empagliflozin/Metformin XR, FDC;   Drug: Empagliflozin/Metformin XR FDC;   Drug: 25 mg Empafliglozin/1000 mg Metformin XR, FDC;   Drug: 1 tablet Empagliflozin/2 tablets Metformin XR;   Drug: 1 tablet Empagliflozin/3 tablets Metformin XR
11 Completed
Has Results
Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid
Condition: Healthy
Interventions: Drug: Probenecid;   Drug: Rifampicin;   Drug: Empagliflozin;   Drug: Empagliflozin (BI 10773)
12 Completed Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: BI 10773 Placebo;   Drug: BI 10773 / BI 1356;   Drug: BI 10773 / BI 1356 Placebo
13 Completed Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets
Condition: Healthy
Interventions: Drug: 1 tablet Empagliflozin/2 tablets Metformin XR;   Drug: 10 mg Empagliflozin/1000 mg Metformin XR;   Drug: 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR;   Drug: 2 tablets 5 mg Empagliflozin/750 Metformin XR
14 Completed
Has Results
Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: Empagliflozin
15 Completed Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together
Condition: Healthy
Interventions: Drug: Empagliflozin;   Drug: Metformin;   Drug: Empagliflozin/Metformin
16 Completed Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets
Condition: Healthy
Interventions: Drug: empagliflozin;   Drug: metformin (Glucophage®);   Drug: empagliflozin and metformin
17 Completed
Has Results
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI10773;   Drug: Placebo
18 Recruiting Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: empagliflozin medium dose;   Drug: empagliflozin high dose;   Drug: empagliflozin low dose
19 Withdrawn Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Empagliflozin;   Drug: Placebo;   Drug: Sitagliptin
20 Not yet recruiting Empagliflozin as Adjunctive to inSulin thErapy in Type 1 Diabetes Over 52 Weeks (EASE-2)
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Empagliflozin;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years